
MSK and Sophia Genetics scale precision oncology
Elite cancer centers are finally trading exclusive data for global scale, shifting the balance of power in precision medicine.
Discover the newest research about AI innovations in 👤 Personalized Medicine.

Elite cancer centers are finally trading exclusive data for global scale, shifting the balance of power in precision medicine.

A new proteomic analysis reveals why Parkinson’s drug trials keep failing despite using biologically pure patient groups.

By training deep learning models to read structural decay in tissue biopsies, researchers can now estimate the biological age of specific organs and predict chronic disease risk.

A new artificial intelligence index uses routine heart scans to calculate mortality risk, proving that how we store fat and muscle matters far more than simple body weight.

A new transformer model can simulate how a patient’s lab values will react to specific drugs before they are even prescribed.

The FDA is letting drugmakers recycle data from past trials to speed up gene therapies, but this regulatory shortcut places a massive burden of proof on developers.

A new self-supervised AI model accurately flags which complex, multi-illness patients are most likely to end up back in the hospital.

Regulators are forcing a public reckoning over whether marginal cancer screening benefits justify the risks of widespread adoption.

Static blood tests are failing HIV patients who seem healthy on paper but remain at risk of silent immune failure.

The federal government is trying to force seven decades of incompatible medical research into a single format that artificial intelligence can actually understand.